Observational studyAnnals of medicine2025

The efficacy and safety of anlotinib plus PD-1 inhibitor in locally advanced/metastatic esophageal squamous cell carcinoma (ESCC) patients who progressed on prior immune checkpoint inhibitors (ICIs): a retrospective real-world study (NCT 04984096).

Xueru Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.